Results 31 to 40 of about 5,265 (145)

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

The Lancet Microbe, 2020
Summary: Background: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy.
Catherine A Chappell, MD, Kimberly K Scarsi, PharmD, Brian J Kirby, PhD, Vithika Suri, MSc, Anuj Gaggar, MD, Debra L Bogen, ProfMD, Ingrid S Macio, PA, Leslie A Meyn, PhD, Katherine E Bunge, MD, Elizabeth E Krans, MD, Sharon L Hillier, ProfPhD   +10 more
doaj   +1 more source

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea [PDF]

Clinical and Molecular Hepatology, 2015
Background/AimsThe previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions.
Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim   +5 more
doaj   +1 more source

SVR in treatment experienced and naïve HCV patients receiving sofosbuvir-based triple therapy

, 2023
SVR in treatment experienced and naïve HCV patients receiving sofosbuvir-based triple therapy. Prior interferon exposure was an important predictor of Sofosbuvir/interferon/ribavirin triple theray SVR acheivement.
Siham Abdel Rehim (14379231), Alaa Abdo (14379222), Hany Ziady (7184144), Abdurrahman Najeeb (14379162), Ehab Elkholy (14379225)   +4 more
core   +1 more source

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form

Future Journal of Pharmaceutical Sciences, 2018
Objective: A simple, specific, accurate and economic reverse phase liquid chromatographic method was developed for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and tablet dosage form.
S.K. Mastanamma, S.K. Chandini, S.K. Reehana, P. Saidulu   +3 more
doaj   +1 more source

Photochemical Reaction Discovery Enabled by the Dynamic Speciation of Copper Complexes

Angewandte Chemie, Volume 138, Issue 41, 5 October 2026.
A strategy for accelerated photochemical reaction discovery is reported that harnesses the dynamic speciation of copper complexes, driven by their labile metal–ligand bonds. This platform simplifies reaction screening by combining an earth‐abundant copper(II) salt with commercially available ligands, which reversibly generate multiple catalytic species
Alessio Regni, Siyu Liang, Supreeta Sen, Hailey Hendricks, Xijue Wu, Matthew V. Pecoraro, Jose B. Roque   +6 more
wiley   +2 more sources

Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19:a systematic review and meta-analysis of randomized trials [PDF]

, 2021
Background: Several randomized trials have evaluated the effects of sofosbuvir-based direct-acting antivirals on the clinical outcomes in patients with COVID-19.
Ramachandram, Dinesh, Javed, Amaan, Kow, Chia Siang, Hasan, Syed Shahzad; id_orcid, Dinesh Ramachandram, Chia Siang Kow, Syed Shahzad Hasan, Amaan Javed   +7 more
core   +1 more source

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes

Scientific Reports
Sofosbuvir is one of the crucial drugs used in the treatment of chronic hepatitis C virus (HCV) in adults and children with compensated liver disease, including cirrhosis. It may be used alone or with other drugs.
Rana A. Ali, Eatemad A. Awadalla, Yahia A. Amin, Samer S. Fouad, Maha Abd-El Baki Ahmed, Mohammed H. Hassan, Emaad Abdel-Kahaar, Rehab H. Abdel-Aziz   +7 more
doaj   +1 more source

Novel combined single dose anti-hepatitis C therapy: a pilot study

Scientific Reports, 2021
The new anti-hepatitis C virus (HCV) molecules improve treatment regimens and outcomes, but there are drawbacks. New combinations should target the HCV infectious cycle and be effective against all HCV genotypes.
Gamal Shiha, Reham Soliman, Mohamed Elbasiony, Noureldien H. E. Darwish, Shaker A. Mousa   +4 more
doaj   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann, Ruy M. Ribeiro, Aurelien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source